Spyre Therapeutics (SYRE) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free SYRE Stock Alerts $37.80 +0.42 (+1.12%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 7:31 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Issues Earnings Results, Misses Estimates By $0.30 EPSSpyre Therapeutics (NASDAQ:SYRE - Get Free Report) released its earnings results on Monday. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30).May 15 at 7:30 AM | prnewswire.comSpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsMay 15 at 4:01 AM | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $40.00 at Wells Fargo & CompanyMay 15 at 12:23 AM | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Short Interest UpdateSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,380,000 shares, an increase of 23.0% from the April 15th total of 3,560,000 shares. Based on an average trading volume of 490,400 shares, the days-to-cover ratio is currently 8.9 days. Currently, 12.8% of the shares of the company are sold short.May 14 at 6:29 PM | markets.businessinsider.comPositive Outlook on Spyre Therapeutics’ IBD Pipeline and Financial StabilityMay 13 at 10:32 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Given New $40.00 Price Target at Wells Fargo & CompanyWells Fargo & Company increased their target price on Spyre Therapeutics from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday.May 12, 2024 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) PT Raised to $40.00 at BTIG ResearchMay 11, 2024 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up After Analyst UpgradeMay 10, 2024 | markets.businessinsider.comSpyre Therapeutics: Strong Buy Recommendation on Robust Pipeline and Financial StabilityMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Spyre Therapeutics’ Promising Pipeline and Expert Team Drive Positive OutlookMay 10, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up on Analyst UpgradeSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up on Analyst UpgradeMay 10, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comSYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024May 9, 2024 | chron.comSpyre Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 5.1% Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.1%May 6, 2024 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Robert W. BairdMay 3, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 3, 2024 | msn.comBaird Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform RecommendationMay 3, 2024 | msn.comCarvana upgraded, Block downgraded: Wall Street's top analyst callsMay 2, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Robert W. BairdRobert W. Baird initiated coverage on shares of Spyre Therapeutics in a report on Thursday. They set an "outperform" rating and a $50.00 target price for the company.April 29, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 6.1%Spyre Therapeutics (NASDAQ:SYRE) Shares Up 6.1%April 24, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 5% Spyre Therapeutics (NASDAQ:SYRE) Shares Down 5%April 23, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by BrokeragesSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price taApril 20, 2024 | investing.comSpyre Therapeutics Inc (SYRE)April 17, 2024 | msn.comSpyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spyre Therapeutics on Promising mAb Dosing and Market PositioningApril 1, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 30, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Large Growth in Short InterestSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 2,880,000 shares, an increase of 34.0% from the February 29th total of 2,150,000 shares. Based on an average daily volume of 450,500 shares, the short-interest ratio is presently 6.4 days. Approximately 9.0% of the shares of the stock are short sold.March 29, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by AnalystsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given an average rating of "Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price objective among brMarch 26, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $54.00Stifel Nicolaus lifted their price target on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday.March 25, 2024 | markets.businessinsider.comStrong Buy Rating for Spyre Therapeutics Based on Promising SPY001 Data and Financial PositionMarch 20, 2024 | investing.comSpyre Therapeutics secures $180 million in PIPE dealMarch 18, 2024 | markets.businessinsider.comSpyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-MarketMarch 18, 2024 | msn.comSpyre Therapeutics climbs 5%, prices $180M private financingMarch 18, 2024 | prnewswire.comSpyre Therapeutics Announces $180 Million Private PlacementMarch 6, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE)March 4, 2024 | msn.comHere's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price StrengthMarch 2, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement AwardsMarch 1, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)March 1, 2024 | markets.businessinsider.comBuy Rating for Spyre Therapeutics: Anticipated Clinical Trials and Strategic Advantages Propel OptimismMarch 1, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded at Wells Fargo & CompanyWells Fargo & Company upgraded shares of Spyre Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $12.00 to $35.00 in a research report on Friday.March 1, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 1, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)February 29, 2024 | prnewswire.comSpyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 26, 2024 | finance.yahoo.comSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceFebruary 26, 2024 | prnewswire.comSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceFebruary 8, 2024 | finance.yahoo.comSpyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis OrganisationFebruary 8, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 6%Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6% Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. SYRE Media Mentions By Week SYRE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.400.55▲Average Medical News Sentiment SYRE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼172▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PCRX News Today MIRM News Today COLL News Today BLTE News Today PRTA News Today MNKD News Today GYRE News Today IRWD News Today VRNA News Today ABCL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe #1 Investment of the Decade… Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge AlertsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
